Ionis Pharmaceuticals. has been granted a patent for methods and compounds aimed at inhibiting IRF4 expression, potentially useful in treating cancers associated with IRF4. The patent includes a claim for a modified oligonucleotide composed of 15 to 30 linked nucleosides with a specific nucleobase sequence. GlobalData’s report on Ionis Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Ionis Pharmaceuticals, Nucleic acid active pharmaceutical ingredient was a key innovation area identified from patents. Ionis Pharmaceuticals's grant share as of June 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
The granted patent US12042510B2 outlines a novel compound consisting of a modified oligonucleotide that is 15 to 30 nucleosides in length. This oligonucleotide features a nucleobase sequence that includes at least 15 contiguous nucleobases from a specified sequence (SEQ ID NO: 2021). The claims detail various modifications that can be incorporated into the oligonucleotide, such as altered internucleoside linkages, sugars, and nucleobases. Notably, the modified internucleoside linkage may be a phosphorothioate, and the modified sugars can include bicyclic variants or 2'-O-methoxyethyl. The structure of the oligonucleotide can also include a gap segment of linked deoxyribonucleotides flanked by wing segments, each containing modified sugars.
Additionally, the patent claims a composition that includes the described compound along with a pharmaceutically acceptable carrier. A significant application of this composition is in the treatment or amelioration of various cancers, including blood cancers such as multiple myeloma, B cell malignancies, lymphomas, and leukemia. The method of administration for the composition is specified to be parenteral, indicating that it may be delivered through injections or infusions. The claims emphasize the potential therapeutic utility of the modified oligonucleotide in oncology, particularly for conditions that are challenging to treat with conventional therapies.
To know more about GlobalData’s detailed insights on Ionis Pharmaceuticals, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
